As university-affiliated laboratories across the US apply to receive NIH funding to become molecular library screening centers, Cellomics and Carl Zeiss want to make sure their product offerings are in the fold.

Two weeks ago, the companies put out a news release stating their intention to “bring small-molecule screening to basic science researchers supported by the National Institutes of Health as part of the Molecular Libraries Screening Centers Network.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.